このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Swedish Orphan Biovitrum マネジメント

マネジメント基準チェック /34

Swedish Orphan Biovitrum'sの CEO はGuido Oelkersで、 May2017年に任命され、の在任期間は 7.08年です。の年間総報酬はSEK 48.88Mで、 25.1%給与と74.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.13%を直接所有しており、その価値はSEK 115.83M 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と3.6年です。

主要情報

Guido Oelkers

最高経営責任者

SEK 48.9m

報酬総額

CEO給与比率	25.1%
CEO在任期間	7.1yrs
CEOの所有権	0.1%
経営陣の平均在職期間	5.4yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Recent updates

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Mar 28

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

Nov 17

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 19

CEO報酬分析

Swedish Orphan Biovitrum の収益と比較して、Guido Oelkers の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

報酬と市場: Guidoの総報酬 ($USD 4.68M ) は、 Swedish市場 ($USD 1.95M ) の同規模の企業の平均を上回っています。

報酬と収益: Guidoの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Guido Oelkers (59 yo)

7.1yrs

在職期間

SEK 48,883,000

報酬

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Guido Oelkers	CEO & President	7.1yrs	SEK 48.88m	0.13% SEK 121.1m
Henrik Stenqvist	Chief Financial Officer	5.9yrs	データなし	0.017% SEK 16.0m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.4yrs	データなし	0.0090% SEK 8.7m
Daniel Rankin	Head of Strategy & Corporate Development	2.4yrs	データなし	0.0052% SEK 5.0m
Lena Bjurner	Head of Human Resources	1.4yrs	データなし	データなし
Armin Reininger	Senior Scientific & Medical Advisor	7.4yrs	データなし	0.011% SEK 10.3m
Norbert Oppitz	Head of International	6.7yrs	データなし	0.012% SEK 11.3m
Sofiane Fahmy	Head of Europe	5.4yrs	データなし	0.0078% SEK 7.5m
Duane Barnes	Head of North America	3.4yrs	データなし	データなし
Mahmood Ladha	Head of Strategic Transformation Operations	no data	データなし	0.0018% SEK 1.8m
Christine Wesstrom	Head of Technical Operations	2.3yrs	データなし	0.0032% SEK 3.1m
Lydia Abad-Franch	Senior VP	1.4yrs	データなし	データなし

5.4yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: SOBIの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Hans Wigzell	Chairman of Scientific Advisory Board	23.4yrs	SEK 158.00k	データなし
Helena Saxon	Director	13.2yrs	SEK 828.00k	0.0067% SEK 6.5m
Anders Ullman	Director	1.1yrs	SEK 463.00k	0.0010% SEK 973.5k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	データなし	データなし
Ralf Pettersson	Member of Scientific Advisory Board	no data	データなし	データなし
Stefan Del Prato	Member of Scientific Advisory Board	no data	データなし	データなし
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	データなし	データなし
Annette Clancy	Independent Chairman	10.1yrs	SEK 770.00k	0.0010% SEK 963.9k
Staffan Schuberg	Independent Director	4.1yrs	SEK 827.00k	0.0021% SEK 2.0m
Filippa Stenberg	Director	3.1yrs	SEK 673.00k	0.00017% SEK 163.9k
Katy Mazibuko	Employee Representative Director	1.4yrs	データなし	0.0018% SEK 1.7m
Christophe Bourdon	Independent Director	1.1yrs	SEK 433.00k	データなし

3.6yrs

平均在職期間

54.5yo

平均年齢

経験豊富なボード: SOBIの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Swedish Orphan Biovitrum マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Recent updates

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

マネジメント基準チェック /34